Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a ...

Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...

The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of ...

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

(Bloomberg) -- Hims & Hers Health Inc. shares surged 24% to close at fresh record after Hunterbrook Media said the company is poised to be a major beneficiary of President-elect Donald Trump’s ...

Hims & Hers Health's stock dropped 25% due to Amazon’s competition. Learn why HIM stock's 38% upside and strong growth make ...

Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Hims & Hers didn’t immediately respond to a request for comment. Hims & Hers shares have gyrated this year after the company started offering copycat versions of GLP-1 injections that are not ...